Long-term safety profile and secondary effectiveness of Canakinumab in Pediatric Rheumatic diseases: a single-center experience

REFERENCES

• Chauhan D, Vande Walle L, Lamkanfi M Therapeutic modulation of inflammasome pathways. Immunol Rev. 2020 Sep;297(1):123–138. 10.1111/imr.12908
   PubMed Web of Science ®Google Scholar
• Sangiorgi E, Rigante D The Clinical Chameleon of Autoinflammatory Diseases in Children. Cells. 2022 Jul 18;11(14). 2231 10.3390/cells11142231
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis. 2018 Nov;77(11):1558–1565.10.1136/annrheumdis-2017-212515
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med. 2003 Jun 19;348(25):2583–4.
   PubMed Web of Science ®Google Scholar
• Yıldız M, Haşlak F, Adrovic A, et al. Autoinflammatory Diseases in Childhood. Balkan Med J. 2020 Aug 11;37(5):236–246.10.4274/balkanmedj.galenos.2020.2020.4.82
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018 May 17;378(20):1908–1919.10.1056/NEJMoa1706314
   PubMed Web of Science ®Google Scholar
• Del Giudice E, Sota J, Orlando F, et al. Off-label use of canakinumab in pediatric rheumatology and rare diseases [Systematic Review]. Frontiers in Medicine. 2022 2022-October-18;9.
   Web of Science ®Google Scholar
• Vitale A, Insalaco A, Sfriso P, et al. A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Front Pharmacol. 2016;7:380. 10.3389/fphar.2016.00380
   PubMed Web of Science ®Google Scholar
• Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015 May;74(5):799–805.10.1136/annrheumdis-2014-206580
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) v5.0 2017. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• Hentgen V, Koné-Paut I, Belot A, et al. Long-Term Follow-Up and Optimization of Interleukin-1 Inhibitors in the Management of Monogenic Autoinflammatory Diseases: Real-Life Data from the JIR Cohort. Front Pharmacol. 2020;11:568865.
   PubMed Web of Science ®Google Scholar
• Dumaine C, Bekkar S, Belot A, et al. Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte. Joint Bone Spine. 2020 Jan;87(1):49–55.10.1016/j.jbspin.2019.07.011
   PubMed Web of Science ®Google Scholar
• Cabrera N, Lega JC, Kassai B, et al. Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database. Joint Bone Spine. 2019 May;86(3):343–350.10.1016/j.jbspin.2018.08.003
   PubMed Web of Science ®Google Scholar
• Song GG, Lee YH Comparison of the efficacy and safety of biological agents in patients with systemic juvenile idiopathic arthritis: A Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021 Mar;59(3):239–246. 10.5414/CP203791
   PubMed Web of Science ®Google Scholar
• Brogan PA, Hofer M, Kuemmerle-Deschner JB, et al. Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger. Arthritis Rheumatol. 2019 Nov;71(11):1955–1963. 10.1002/art.41004
   PubMed Web of Science ®Google Scholar
• Walker UA, Tilson HH, Hawkins PN, et al. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry. RMD Open. 2021 May;7(2). e001663 10.1136/rmdopen-2021-001663
   PubMed Web of Science ®Google Scholar
• Vinit C, Georgin-Lavialle S, Theodoropoulou A, et al. Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review. Front Immunol. 2021;12:744780. 10.3389/fimmu.2021.744780
   PubMed Web of Science ®Google Scholar
• Abadie BQ, Cremer PC Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis. BioDrugs. 2022 Jul;36(4):459–472.10.1007/s40259-022-00537-7
   PubMed Web of Science ®Google Scholar
• Hosono K, Matsumoto K, Shimbo M, et al. Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: Interim results from post-marketing surveillance in Japan. Mod Rheumatol. 2023 Mar 2;33(2):381–391. 10.1093/mr/roac041
   PubMed Web of Science ®Google Scholar
• Coşkuner T, Çağlayan Ş, Akgün Ö, et al. The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study. Expert Opin Biol Ther. 2023 Nov 16:1–8.
   Google Scholar
• Ozen S, Ben-Cherit E, Foeldvari I, et al. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Ann Rheum Dis. 2020 Oct;79(10):1362–1369.10.1136/annrheumdis-2020-217419
   PubMed Web of Science ®Google Scholar
• Jeyaratnam J, Simon A, Calvo I, et al. Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial. Rheumatology (Oxford). 2022 May 5;61(5):2088–2094.10.1093/rheumatology/keab696
   PubMed Web of Science ®Google Scholar
• Gattorno M, Obici L, Penadés IC, et al. Long-term efficacy/safety of canakinumab in patients with tumor necrosis factor receptor-associated periodic syndrome: results from a phase III trial. Arthritis Rheumatol. 2023 Sep 5.
   Web of Science ®Google Scholar
• Adrovic A, Yildiz M, Köker O, et al. Biologics in juvenile idiopathic arthritis-main advantages and major challenges: A narrative review. Arch Rheumatol. 2021 Mar;36(1):146–157.
   PubMed Web of Science ®Google Scholar
• Alexeeva E, Krekhova E, Dvoryakovskaya T, et al. Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data. Front Pediatr. 2023;11:1114207. 10.3389/fped.2023.1114207
   PubMed Web of Science ®Google Scholar
• Brunner HI, Quartier P, Alexeeva E, et al. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. Arthritis Rheumatol. 2020 Dec;72(12):2147–2158. 10.1002/art.41436
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018 Dec;77(12):1710–1719.10.1136/annrheumdis-2018-213150
   PubMed Web of Science ®Google Scholar
• Klein A, Klotsche J, Hügle B, et al. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatology (Oxford). 2020 Sep 1;59(9):2287–2298.10.1093/rheumatology/kez577
   PubMed Web of Science ®Google Scholar
• Swart J, Giancane G, Horneff G, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018 Dec 27;20(1):285.10.1186/s13075-018-1780-z
   PubMedGoogle Scholar
• Hosono K, Kato C, Sasajima T Real-world safety and effectiveness of canakinumab in patients with cryopyrin-associated periodic fever syndrome: a long-term observational study in Japan. Clin Exp Rheumatol. 2022 Sep;40(8):1543–1553. 10.55563/clinexprheumatol/pjs6eh
   PubMed Web of Science ®Google Scholar
• Kurt T, Aydın F, Nilüfer Tekgöz P, et al. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience. Int J of Rheum Dis. 2020 Jul;23(7):977–981. 10.1111/1756-185X.13891
   PubMed Web of Science ®Google Scholar
• Brik R, Butbul-Aviel Y, Lubin S, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol. 2014 Nov;66(11):3241–3243. 10.1002/art.38777
   PubMed Web of Science ®Google Scholar
• Başaran Ö, Uncu N, Çelikel BA, et al. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol. 2015 Jul;25(4):621–624. 10.3109/14397595.2014.987437
   PubMed Web of Science ®Google Scholar
• Gülez N, Makay B, Sözeri B Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients. Mod Rheumatol. 2020 Jan;30(1):166–171. 10.1080/14397595.2018.1559488
   PubMed Web of Science ®Google Scholar
• Arostegui JI, Anton J, Calvo I, et al. Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome. Arthritis Rheumatol. 2017 Aug;69(8):1679–1688. 10.1002/art.40146
   PubMed Web of Science ®Google Scholar
• Sözeri B, Demir F, Barut K, et al. Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey: the TURSIS study. Clin Exp Rheumatol. 2023 Jul 24. 10.55563/clinexprheumatol/j611kr
   Web of Science ®Google Scholar